5 completed, 2 terminated. 3 Phase 4, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Terminated 2, Completed 1 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow polystyrene sulfonic acid: new trials by email Literature Review of polystyrene sulfonic acid trials Research Report on polystyrene sulfonic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients sodium zirconium cyclosilicate (SZC), sodium polystyrene sulfonate - Hyperkalemia | Not applicable | Completed | Alexandria University | 120 | 2024-01-15 | 2025-02-11 |
| The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels Renastart formula, calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally. - Acute Kidney Injury | Not applicable | Completed | Ain Shams University | 24 | 2022-02-12 | 2024-02-05 |
| Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water - Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure | Completed | AstraZeneca | 147 | 2020-10-23 | 2023-11-07 | |
| Comparison of Potassium Binders in the ER Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer - Acute Hyperkalemia, Oral Potassium Binders | Phase 4 | Terminated | University of California, Irvine | 37 | 2020-10-20 | 2026-04-22 |
| Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients Sodium polystyrene sulfonate, Lactose with carob gum - Hyperkalemia, Chronic Kidney Failure | Phase 4 | Completed | Maisonneuve-Rosemont Hospital | 38 | 2014-02-01 | 2014-10-03 |
| Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia Sodium polystyrene sulfonate, Silicified microcrystalline cellulose - Hyperkalemia | Phase 4 | Terminated | ZS Pharma, Inc. | 32 | 2013-05-01 | 2014-09-03 |
| Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I enalapril, polystyrene sulfonate - Pseudohypoaldosteronism | Phase 2 | Completed | National Center for Research Resources (NCRR) | 1 | 1992-12-01 | 2005-06-24 |
Hyperkalemia (4) · Acute Kidney Injury (1) · Emergencies (1) · Endocrine System Diseases (1) · Kidney Failure, Chronic (1) · Pseudohypoaldosteronism (1) · Rare Diseases (1) · Renal Insufficiency, Chronic (1)
Ain Shams University (1) · Alexandria University (1) · AstraZeneca (1) · Maisonneuve-Rosemont Hospital (1) · National Center for Research Resources (NCRR) (1) · University of California, Irvine (1) · ZS Pharma, Inc. (1)
United States (3) · Canada (2) · Egypt (2) · France (1) · Italy (1) · Spain (1) · Sweden (1)
Bruce S. Keenan (1) · Eric Wittbrodt, PharmD, MPH (1) · Haya E Ibrahim, MD (1) · Henrik Rasmussen, MD (1) · Marwa Ahmed Abdelrahman, MD (1) · Mohamed Aly Abdelhalim, MD (1) · Mohamed Mamdouh Elsayed, MD (1) · Vincent Pichette, MD (1)
PMID 32588430, PMID 37016309, PMID 38387989, PMID 38835400, PMID 40329202